Effects of erythropoiesis stimulating agentin on heart failure patients with reduced left ventricular function and the cardiorenal anemia syndrome

Effects of erythropoiesis stimulating agentin on heart failure patients with reduced left ventricular function and the cardiorenal anemia syndrome - Effects of erythropoiesis stimulating agent on heart failure patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010762

Enrollment

100

Registered

2013-05-20

Start date

2013-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic heart failure patients with reduced left ventricular function

Interventions

with anemia without anemia

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Hb<12g/dl and eGFR<60ml/min/1.73m2 for atleast 3 months 2. Optimal pharmacologic therapy including ACEI, ARB and beta-blockers 3. TSAT>15.0%, Vit B12, folate concentration in the normal range

Exclusion criteria

Exclusion criteria: 1. uncontrolled hypertension (>160/100 mmHg) 2. previous history of cardiovascular disease within 3 months 3. new-onset of atrial fibrillation and atrial flutter within one month 4. Cr>3mg/dl 5. renal transplantation within 6 months, or chemo and radiation therapy within 12 months. Previous history of malignant disease, hematological disorder. 6. allergy of ESA

Design outcomes

Primary

Measure	Time frame
Sudden cardiac death, death and hospitalization due to worsening heart failure	—

Countries

Japan

Contacts

Public ContactKobe University Graduate School of Medicine

Kobe University Graduate School of Medicine Division of Cardiovascular Medicine

tanakah@med.kobe-u.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026